US 12,343,535 B2
Vagus nerve stimulation to treat neurodegenerative disorders
Jacob A. Levine, West Hempstead, NY (US); Nicole Hamlin, Centereach, NY (US); David Chernoff, Sausalito, CA (US); and Manojkumar Gunasekaran, Valencia, CA (US)
Assigned to SetPoint Medical Corporation, Valencia, CA (US)
Appl. No. 17/599,594
Filed by SETPOINT MEDICAL CORPORATION, Valencia, CA (US)
PCT Filed Apr. 13, 2020, PCT No. PCT/US2020/027906
§ 371(c)(1), (2) Date Sep. 29, 2021,
PCT Pub. No. WO2020/210786, PCT Pub. Date Oct. 15, 2020.
Claims priority of provisional application 62/833,631, filed on Apr. 12, 2019.
Prior Publication US 2022/0193413 A1, Jun. 23, 2022
Int. Cl. A61N 1/36 (2006.01); A61N 1/05 (2006.01)
CPC A61N 1/36053 (2013.01) [A61N 1/3606 (2013.01); A61N 1/36103 (2013.01); A61N 1/36135 (2013.01); A61N 1/36171 (2013.01); A61N 1/0556 (2013.01); A61N 1/36175 (2013.01)] 13 Claims
OG exemplary drawing
 
13. A system for reducing demyelination and/or increasing remyelination by stimulation of a vagus nerve, the system comprising:
a vagus nerve stimulator configured to be implanted over or adjacent to a vagus nerve;
one or more electrodes on the vagus nerve stimulator configured to apply electrical stimulation to the vagus nerve; and
a controller coupled to the vagus nerve stimulator and configured to apply electrical stimulation to the vagus nerve from the one or more electrodes to reduce demyelination and/or increase remyelination in central nervous system nerves within a patient, wherein the controller is constrained to limit a total charge per day to between 2.5 nC and 7.5 mC to reduce demyelination and/or increase remyelination within the patient by increasing clearance of neuronal cellular debris by phagocytosis and efferocytosis,
further wherein the controller is configured to limit a frequency of the electrical stimulation to less than a maximum of 30 Hz.